If you enjoy this content, please share it with a colleague
Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.
RELATED CONTENT
Elekta announced that Providence Health and Services in Renton, Wash., the nation's third largest not-for-profit health ...
Three foremost medical centers in the United Kingdom and Germany have ordered and are now planning upgrades to Elekta's latest generation stereotactic radiosurgery system for the brain, Leksell Gamma Knife Icon. The centers are: University Medical Centre Mannheim (UMC, Mannheim, Germany); Bristol Gamma Knife Centre, University Hospitals Bristol NHS Foundation Trust (Bristol, U.K.); and The Leeds Gamma Knife Centre at St James's Institute of Oncology (Leeds, U.K.).
Image-guided radiation therapy (IGRT) affords greater accuracy of dose distribution during cancer treatment, allowing the radiation oncologist to see how a tumor is responding over the course of treatment. This has traditionally been accomplished with computed tomography (CT) or X-ray scans, which requires extra radiation exposure for the patient, with relatively poor contrast in soft tissue due to uniform electron density. Since treatment is only as good as the images provided, efforts are under way to find a better modality — and magnetic resonance imaging (MRI) may hold the answer.
The ECRI Institute released a new techIQ brief on key factors to consider when purchasing a linear accelerator (linac) for external beam radiation therapy. The report is a compilation of results from a survey of hundreds of users of linac-based radiosurgery systems; participants were asked to rate the functions and features of the four major linac vendors: Accuray, Brainlab, Elekta and Varian Medical Systems.
Brainlab announced first patient treatments in March on a fully integrated radiation oncology solution that combines its ExacTrac patient positioning with the Elekta Versa HD linear accelerator (LINAC). Working in synergy, these technologies determine positioning and treatment accuracy for cancer patients.
On June 16, 2015, William Beaumont Hospital and Elekta Ltd. filed a patent infringement suit against Varian Medical Systems Inc. in the United States District Court for the Eastern District of Michigan.
Together with its customers, Elekta raised EUR 30,575 (USD 33,250) during the 3rd European Society for Therapeutic Radiology and Oncology (ESTRO) Forum in Barcelona in April. The funds will be donated to Radiating Hope, a nonprofit organization with the mission to improve cancer care, specifically radiation oncology care, around the world.
Today, treatment planning — the heart of radiation therapy systems — is almost entirely computer based, and is designed to help increase productivity by simplifying data for clinicians, making workflow smooth and seamless. This is key to helping improve patient outcomes. As technology progresses, so do treatment planning systems.
With the introduction of Elekta's new Leksell Gamma Knife Icon, the benefits of precision cranial radiosurgery are now available for more patients with a wider variety of tumor types and sizes. This latest generation stereotactic radiosurgery system for the brain integrates advanced motion management, dose delivery and imaging technologies, significantly increasing the versatility of Gamma Knife radiosurgery. Elekta unveiled Leksell Gamma Knife Icon at the 3rd European Society for Therapeutic Radiology and Oncology (ESTRO) Forum in Barcelona.
At the American Association of Neurological Surgeons (AANS) annual meeting, May 2-6 in Washington, D.C., Elekta highlighted Leksell Gamma Knife Registry. The cloud-based solution enables clinicians to leverage the data generated by thousands of Gamma Knife radiosurgery treatments each year to advance clinical research and further optimize patient care.